FDA Clears MIRARI® Cold Plasma System, Marking a First for Handheld Atmospheric Plasma Devices
Apr 10, 2026
General Vibronics PR
News
General Vibronics has secured FDA 510(k) clearance for its MIRARI® Cold Plasma System (GV-M2-01), a portable, battery-operated medical device that generates cold atmospheric plasma using ambient air — making it the first handheld device of its kind to achieve this regulatory milestone in the United States. The clearance, granted on November 21, 2024 under number K242553, arrives as the global cold plasma in healthcare market surges toward a projected USD 6.31 billion by 2031 at a 14.62% CAGR[1][2], and as Germany becomes the first country to assign dedicated reimbursement codes for cold plasma treatments[2].
The FDA determined that the MIRARI® Cold Plasma System is substantially equivalent to a legally marketed predicate device — the TempSure FlexSure Applicator (K200241) — and classified it under 21 CFR 878.4400 (Class II medical device)[3]. The device’s approved indication for use states: “MIRARI® Cold Plasma System provides heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms and increase in local circulation”[3].
Designed and manufactured exclusively at General Vibronics’ U.S. headquarters in Tempe, Arizona, the system weighs approximately 1 lb and operates at a resonant frequency of 80 kHz using Dielectric Barrier Discharge (DBD) technology[3]. Unlike plasma jet devices that require helium or argon gas — consumables that now cost USD 80–120 per cylinder following U.S. reserve sales[2] — the MIRARI® system ionizes ambient air, eliminating noble-gas dependencies entirely[3][4].
This clearance carries broader regulatory significance. According to Mordor Intelligence’s 2026 healthcare market analysis, the FDA clearance of the MIRARI® system for dermal wounds “created a predicate device that eases future 510(k) filings” for other cold plasma manufacturers[2]. In an industry where regulatory dossiers and clinical evidence remain key market-entry barriers, K242553 establishes a new reference point for the entire handheld CAP device category.
The 510(k) submission included comprehensive verification and validation testing[3]:
Thermal testing demonstrated that the device maintains a therapeutic temperature within ±2°C of the target for the full 10-minute treatment protocol, verified across three test subjects with all electrode configurations[3].
Cold atmospheric plasma generates biologically active reactive oxygen and nitrogen species (ROS/RNS) that interact with tissue through multiple clinically relevant pathways[5]. A comprehensive systematic review published in Frontiers in Medicine in February 2025 confirmed three principal mechanisms[5]:
Antimicrobial action and biofilm disruption. CAP-generated ROS/RNS disrupt microbial cell membranes and neutralize biofilms — structures that protect bacteria from both antibiotics and the host immune system. The Mordor Intelligence report noted that CAP achieves 3- to 5-log reductions in multidrug-resistant Pseudomonas and Acinetobacter on hospital surfaces, outperforming chemical disinfectants that require 10 minutes of contact time[2]. In a landmark randomized controlled trial published in Nature Scientific Reports, 58.97% of patients treated with a CAP-jet achieved complete healing of chronic ulcers after 6 weeks, compared to only 5.13% in the standard dressing control group[6].
Anti-inflammatory modulation. Plasma interacts with immune cells and molecular mediators at the tissue level, modulating cytokine expression and recruiting immune cells to support the healing cascade without causing chronic inflammation[5].
Tissue regeneration stimulation. CAP enhances fibroblast proliferation, keratinocyte migration, angiogenesis, collagen synthesis, and epithelialization[5]. The Frontiers in Medicine review also noted evidence that CAP may help prevent scar formation by suppressing TGF-β1 and lowering α-SMA and COL1 expression, with treated acute wounds in animal models showing significantly reduced scar width[5].
| Technical Specification | MIRARI® Cold Plasma System | TempSure FlexSure (Predicate) |
|---|---|---|
| Energy type | Radiofrequency | Radiofrequency |
| Modality | Dielectric Barrier Discharge (DBD) | Diathermy by high-voltage insulated electrode |
| Output frequency | 80 kHz | 4.0 MHz |
| Total power | < 4W | < 300W |
| Electric field | < 80 V/m | < 1,200 V/m |
| Weight | 1 lb | 30 lbs |
| Gas requirement | Ambient air (none) | N/A |
| Treatment area | 29 cm² | Varies by applicator size |
| Patient contact material | Polyester fleece (300 g/m²) | Gold-plated aluminum, PVDF, hydrogel |
Source: FDA 510(k) Summary K242553[3]
The MIRARI® clearance arrives during a period of rapid market expansion and regulatory momentum for cold plasma technologies globally.
Germany leads reimbursement. In Q4 2024, Germany’s Federal Joint Committee (G-BA) added cold plasma to its EBM fee schedule, granting dedicated billing codes for three devices — PlasmaDerm Flex (EUR 35.21), Plasma Care (EUR 20.29), and kINPen MED (EUR 29.83) — subject to ongoing real-world evidence collection[2]. This marks the first time any national healthcare system has formally integrated cold plasma into its reimbursement structure.
Asia-Pacific emerges as the growth engine. Japan’s PMDA fast-tracked handheld jet approvals and authorized Plasma Care for room disinfection, while China finalizes Class III oncology rules for CAP applications. The Asia-Pacific region is projected to grow at a 16.83% CAGR through 2031[2].
RF technology gains share over helium jets. Plasma jets held 41.57% of device revenue in 2025, but helium supply volatility is pushing the industry toward radio-frequency systems that operate on ambient air. RF systems are forecast to grow at a 17.35% CAGR, aided by guidelines from Germany’s Robert Koch Institute citing 99.9% sporicidal efficacy in 90 seconds[2]. As a DBD/RF device requiring no noble gases, the MIRARI® system is positioned directly within this accelerating technology shift.
Scientific validation expands. In October 2025, the European Wound Management Association (EWMA) published a clinical document concluding that CAP holds great promise as a sustainable advanced therapy in wound treatment, while calling for standardized protocols and expanded randomized controlled trials[7]. This followed a February 2026 case report documenting successful adjunctive CAP therapy for a chronic post-surgical wound, achieving complete healing and bacterial eradication after 19 sessions without adverse effects[8].
For U.S. healthcare providers, the K242553 clearance opens several pathways. The device’s prescription-use classification allows physicians to deploy it in clinical settings for pain management, muscle spasm relief, and circulation enhancement[3]. Its 1-lb weight and battery-operated design make it suitable for ambulatory surgical centers — a segment projected to grow at a 19.63% CAGR as hand-piece models under USD 15,000 fit ASC budgets[2].
General Vibronics has stated that the device is backed by granted U.S. patents and multiple international innovation awards, with clinical partnerships already established in international markets[4]. According to the company’s authorized distributor, the technology platform leverages 42 patents held by General Vibronics[4].
However, important limitations remain. The U.S. Centers for Medicare and Medicaid Services (CMS) has not yet established national coverage for cold plasma devices, citing insufficient cost-effectiveness data and short follow-up periods in existing trials[2]. As the EWMA document and the Frontiers in Medicine review both emphasize, the field still needs standardized clinical protocols, large-scale RCTs, long-term safety assessments, and reimbursement frameworks before CAP becomes a routine clinical modality[5][7].
The FDA clearance of the MIRARI® Cold Plasma System represents both a regulatory milestone for General Vibronics and a broader inflection point for the cold atmospheric plasma field in the United States. As reimbursement frameworks mature in Europe and clinical evidence continues to accumulate globally, the path from clearance to widespread clinical adoption will depend on rigorous post-market studies and payer engagement. Follow this space for continued coverage as the cold plasma landscape evolves.
Homepage
Cold Plasma: An Emerging Technology for Clinical Use in Wound Healing
